Silence Therapeutics (SLN)

Company name:Silence Therapeutics Plc
Company Description:A group engaged in biotechnology research and development in the UK Germany and the United States
EPIC:SLNTrading Currency:GBX
Market Sector:ASM6ISIN:GB00B9GTXM62
Market Segment:AMSMShare Type:DE
WWW Address: 5P
 Price Price Change [%] Bid Offer Open High Low Volume
 575.00 -35.0 [-5.74] 570.00 575.00 610.00 610.00 570.00 114,396
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 449.04 78.09 -0.02 -26.20 - - - 610.00 - 40.00

Silence Therapeutics Key Figures

(at previous day's close)
Market Cap.449.04m
Shares In Issue78.09m
Prev. Close610.00
PE Ratio- 
Dividend Yield-%
EPS - basic-26.20p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-21.46p
Return On Equity (ROE)-52.52%
Operating Margin-%
PEG Factor- 
EPS Growth Rate-1,039.13%
Dividends PS Growth Rate-%
Net Debt-17.66m
Gross Gearing9.85%
Quick Assets29.50m
Net Working Capital25.67m
Intangibles / Fixed Assets87.26%
Turnover PS-p
Pre-Tax Profit PS-26.28p
Retained Profit PS-23.58p
Cash PS27.52p
Net Cash PS22.62p
Net Tangible Asset Value PS *34.40p
Net Asset Value PS44.89p
Spread5.00 (0.87%) 

Silence Therapeutics Balance Sheet


Share Price Performance

Sample Period HighLow
1 week610.00488.00
4 weeks610.00370.00
12 weeks610.00165.00
1 year610.0040.00

Share Price Chart (5 years)

Silence Therapeutics Historic Returns

Period OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week498.0077.0015.46488.000.13552.99
4 weeks400.00175.0043.75370.000.11474.42
12 weeks192.00383.00199.48165.000.20277.48
26 weeks54.00521.00964.8142.000.32154.09
1 year86.20488.80567.0540.000.20142.42
3 years109.00466.00427.5240.000.12152.29
5 years225.00350.00155.5640.000.09157.29

Silence Therapeutics Key Management Ratios

Silence Therapeutics Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 9.57 
Tobin's Q Ratio (excl. intangibles)11.57 
Dividend Yield-%
Market-to-Book Ratio12.81 
Price-to-Pre-Tax Profit PS-21.88 
Price-to-Retained Profit PS-24.39 
Price-to-Cash Flow PS-26.79 
Price-to-Sales PS- 
Price-to-Net Tangible Asset Value PS16.72 
Price-to-Cash PS20.89 
Net Working Capital PS32.87 
Price Pct to Working Capital PS17.49%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Silence Therapeutics Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing-45.43%
Net Gearing (excl. Intangibles)-57.55%
Gross Gearing9.85%
Gross Gearing (excl. Intangibles)12.48%
Gearing Under 1 Year9.85%
Gearing Under 1 Year (excl. Intgbl)12.48%
(Liquidity Ratios)
Net Working Capital to Total Assets66.01%
Current Ratio7.70 
Quick Ratio (Acid Test)7.70 
Liquidity Ratio5.61 
Cash & Equiv/Current Assets72.87%
(Solvency Ratios)
Enterprise Value427.55m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.01 
Total Debt/Sales- 
Total Debt/Pre-Tax Profit-0.19 
Total Debt3.83m
Total Debt/Net Current Assets0.15%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs9 
Beta (60-Mnth)Beta (36-Mnth)

Silence Therapeutics Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-58.55%
Return On Assets (ROA)-39.22%
Net Profit Margin-%
Assets Turnover- 
Return On Equity (ROE)-52.52%
Return On Investment (ROI)-42.13%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-%
(Asset Utilisation Multiples)
Shareholders Equity Turnover- 
Fixed Assets Turnover- 
Current Assets Turnover- 
Net Working Capital Turnover 
Inventory Turnover- 
(Other Operating Ratios)
Total Assets-to-Sales- 
Debt Collection Period-Days

Silence Therapeutics Dividends

Sorry No Data Available

Silence Therapeutics Fundamentals

 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
pre tax profit-9.43--10.36--3.78--20.53-m
attributable profit-6.65--8.44--1.62--18.41-m
retained profit-6.65--8.44--1.62--18.41-m
eps - basic (p)-10.40 -12.10 -2.30 -26.20 
eps - diluted (p)-10.40 -12.10 -2.30 -26.20 
dividends per share- - - - 

Silence Therapeutics Balance Sheet

 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
 31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
fixed assets fixed assets1.091.78%1.382.46%1.172.13%0.922.37%m
intangibles intangibles6.6710.84%7.7513.90%8.0614.65%8.1921.06%m
fixed investments fixed investments0.000.00%4.427.92%0.320.58%0.280.71%m
current assets - other current assets - other--%--%--%5.9215.23%m
stocks stocks--%--%--%--%m
debtors debtors1.873.04%3.235.79%2.724.94%2.085.35%m
cash & securities cash & securities51.9184.34%39.0169.92%42.7577.71%21.4955.28%m
creditors - short creditors - short1.121.82%1.612.89%2.664.83%3.839.85%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves60.4398.18%54.1897.11%52.3595.17%35.0690.15%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Silence Therapeutics Cash Flow Statement

31 Dec 2015 (GBP)31 Dec 2016 (GBP)31 Dec 2017 (GBP)31 Dec 2018 (GBP)
Operating CF-8.26-10.07-9.60-16.76m
Pre-Financing CF-3.93-14.743.42-21.59m
Retained CF35.22-14.843.46-21.25m

Silence Therapeutics Brokers

Nomura Code Securities LimitedMarket Maker(MME)Broker/DealerCODECODCGB21
Collins Stewart Europe LimitedMarket Maker(MME)Broker/DealerCSCSCSTEGB21
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MME)Broker/DealerJEFFJEFFGB2X
Liberum Capital LimitedMarket Maker(MME)Broker/DealerLIBCLCAPGB21
Shore Capital Stockbrokers LtdMarket Maker(MME)Broker/DealerSCAPSHOCGB21
Merrill Lynch InternationalMarket Maker(MME)Broker/DealerMLSBSNCSGB2LBIC
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
Silence Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191205 14:43:58